Saturday 17 October 2026 Export UTMD’s income statement to Excel — free account

Utah Medical Products, Inc.

UTMD Healthcare Medical Instruments & Supplies

Utah Medical Products, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.5 million, down 5.83% from fiscal 2024. In the quarter to June 2026, revenue fell 14.3%, EPS fell 10.6% and free cash flow fell 55.7%, each against the same quarter a year earlier. Dividend growth for three consecutive years.

74.51 0.41 −0.55%

Follow UTMD

Alert me

Market cap: $237.8M
P/E: 22.7×
Fwd P/E: 28.7×
Dividend yield: 1.66%
F-score: 6/9
Altman Z: 36.25
Beneish M: −2.68
Dividend safety: 82/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 7.35%

Capital & Financial Ratios $m

Market Cap 237.78

Revenue 36.11

Net Income 10.49

Free Cash Flow 11.45

Net Debt (87.53)

Current Ratio 48.62

Debt/Equity 0.00

P/E ratio 22.72

Fwd P/E 28.70

P/S ratio 6.57

P/B ratio 1.94

Past 5Y EPS Growth 3.43%

This Y EPS Growth —

Next Y EPS Growth —

Next Y revenue growth (10.03%)

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 70.29%

10-year low 10-year high

P/S against its own 10 years 53.63%

10-year low 10-year high

P/B against its own 10 years 21.93%

10-year low 10-year high

EV/Sales against its own 10 years 26.39%

10-year low 10-year high

EV/FCF against its own 10 years 52.40%

10-year low 10-year high

Dividends

Payout Ratio 0.38

Annual Dividend Rate 1.24

Annual Dividend Yield 1.66%

	total	individual payouts
2026	0.93	0.31 0.31 0.31
2025	1.23	0.31 0.31 0.31 0.31
2024	1.21	0.30 0.30 0.30 0.31
2023	1.19	0.30 0.30 0.30 0.30
2022	1.17	0.29 0.29 0.29 0.30
2021	0.86	0.29 0.29 0.29 2.00
2020	1.13	0.28 0.28 0.28 0.29
2019	1.11	0.28 0.28 0.28 0.28
2018	1.09	0.27 0.27 0.27 0.28
2017	1.07	0.27 0.27 0.27 0.27
2016	1.05	0.26 0.26 0.26 0.27

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	93	83	86	88
Receivables	3	4	4	4
Inventory	10	9	8	9
Other	—	—	—	—
	106	96	98	101

	2023	2024	2025	Q'26
Payables	1	1	1	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	5	4	3	2

Compound Annual Growth %

	10y	5y	3y
Sales	(0.42%)	(1.80%)	(9.68%)
Cash Flow	0.63%	(6.11%)	(11.43%)
Earnings	(0.48%)	0.89%	(11.84%)
Book Value	5.53%	3.01%	1.44%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	9	9	—	—	—
’25	10	10	10	9	39
’24	11	10	10	9	41
’23	13	13	13	12	50
’22	12	13	13	14	52
’21	11	13	13	13	49
’20	11	9	10	12	42

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	3	1	—	—	—
’25	4	3	4	3	15
’24	5	3	4	3	15
’23	7	5	5	5	22
’22	5	5	6	6	21
’21	6	5	6	5	21
’20	6	4	5	6	20

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	3	1	—	—	—
’25	4	3	4	3	14
’24	5	3	4	3	15
’23	7	5	5	5	22
’22	5	5	5	6	20
’21	6	4	6	5	21
’20	5	3	5	6	19

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.82	0.84	—	—	—
’25	0.92	0.94	0.82	0.80	3.48
’24	1.09	0.98	1.02	0.86	3.96
’23	1.16	1.15	1.08	1.18	4.57
’22	0.96	1.12	1.18	1.25	4.52
’21	0.83	0.94	1.15	1.13	4.04
’20	0.84	0.36	0.80	0.93	2.94

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	54.20	58.50	73.98	76.60	75.33	81.01	80.10	75.00	60.39	51.26	Analyst estimates 2026–2028 Powerpack
	High	75.00	85.00	117.65	112.26	109.99	133.87	109.50	101.41	85.76	65.56
People
People	Employees	184	183	173	193	192	211	221	190	167	152
	Revenue/emp, $m	0.21	0.23	0.24	0.24	0.22	0.23	0.24	0.26	0.24	0.25
Income, $m
Income, $m	Revenue	39	41	42	47	42	49	52	50	41	39
	Gross margin, %	60.28	63.73	62.64	62.82	60.57	63.03	61.58	59.81	59.03	57.12
	EBT	16	19	19	18	14	19	21	20	17	14
	EBT margin, %	41.79	46.08	46.33	38.13	32.81	38.86	39.52	40.00	41.08	36.63
	Net income	12	9	19	15	11	15	16	17	14	11
	Depreciation	3	3	3	7	7	7	7	6	3	3
Per share, $
Per share, $	Revenue	10.48	11.14	11.26	12.61	11.53	13.45	14.37	13.84	11.68	11.89
	Earnings	3.22	2.28	4.95	3.94	2.94	4.04	4.52	4.57	3.96	3.48
	Cash flow	3.87	4.55	4.51	4.58	5.50	5.81	5.81	6.14	4.23	4.53
	Capex	(0.88)	(0.43)	0.12	(5.79)	(0.24)	(0.15)	(0.22)	(0.18)	(0.06)	(0.11)
	Free cash flow	2.99	4.12	4.64	(1.21)	5.27	5.66	5.59	5.96	4.17	4.42
	Book value	18.46	21.01	23.86	27.17	28.11	29.38	31.41	35.36	33.52	36.81
	Shares, m	4	4	4	4	4	4	4	4	4	3
Valuation, ×
Valuation, ×	P/E	22.24	34.63	16.78	27.39	28.77	24.69	21.68	18.27	15.56	16.08
	P/S	6.82	7.12	7.38	8.56	7.31	7.43	6.80	6.03	5.26	4.71
	P/B	3.87	3.77	3.48	3.97	3.00	3.40	3.11	2.36	1.83	1.52
	EV/Sales	6.17	6.18	6.18	7.67	6.11	6.21	5.38	4.20	3.26	2.51
	EV/FCF	21.60	16.72	15.02	(80.21)	(149.60)	(873.06)	13.85	9.75	9.12	6.74
Cash, $m
Cash, $m	Operating cash flow	15	17	17	17	20	21	21	22	15	15
	Capex	(3)	(2)	0	(22)	(1)	(1)	(1)	(1)	0	0
	Free cash flow	11	15	17	(4)	19	21	20	22	15	14
Balance, $m
Balance, $m	Working capital	31	44	56	51	58	69	84	102	93	95
	Total debt	—	—	—	0	0	0	0	—	—	—
	Net debt	(26)	(40)	(51)	(43)	(52)	(61)	(75)	(93)	(83)	(86)
	Shareholders’ equity	69	78	89	101	103	107	114	128	117	119
Returns, %
Returns, %	ROA	15.61	10.07	19.28	14.06	9.75	13.01	13.76	12.83	10.76	9.21
	ROIC	23.59	31.13	30.85	18.90	16.72	25.56	31.55	29.58	24.66	21.26
	ROE	17.46	11.54	22.21	15.50	10.59	14.09	14.88	13.72	11.29	9.54

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NNNN Anbio Biotechnology	$474.8M	—	—	—	—	—	—	—	Compare
EMBC Embecta Corp.	$365.5M	4.2×	3.8×	−8.05% (below 0%: shrinking)	−53.85% (below 0%: shrinking)	−49.63% (below 0%: shrinking)	56.42%	17.92%	Compare
ZJYL Jin Medical International Ltd.	$340.9M	—	—	—	—	−8,074.17% (below 0%: shrinking)	34.44%	0.00%	Compare
SMTI Sanara MedTech Inc.	$322.4M	— (loss-making)	125×	+9.04% (above 0%: growing)	n/m	+131.28% (above 0%: growing)	92.96%	6.33%	Compare
OSUR OraSure Technologies, Inc.	$262.8M	— (loss-making)	— (loss-making)	−1.93% (below 0%: shrinking)	n/m	−1.40% (below 0%: shrinking)	43.46%	17.76%	Compare
UTMD Utah Medical Products, Inc.	$237.8M	22.7×	28.7×	−14.31% (below 0%: shrinking)	−10.64% (below 0%: shrinking)	−55.74% (below 0%: shrinking)	55.79%	31.06%
PDEX Pro-Dex, Inc.	$194.1M	13.8×	23.5×	+16.65% (above 0%: growing)	+143.24% (above 0%: growing)	−78.95% (below 0%: shrinking)	34.75%	17.29%	Compare
KRMD KORU Medical Systems, Inc.	$139.9M	— (loss-making)	— (loss-making)	+18.15% (above 0%: growing)	n/m	+26.17% (above 0%: growing)	65.14%	5.21%	Compare
NYXH Nyxoah SA	$121.2M	— (loss-making)	— (loss-making)	+486.62% (above 0%: growing)	n/m	+4.01% (above 0%: growing)	59.73%	(268.25%)	Compare
Median of peers	$292.6M	—	23.5×	+12.85%	—	−1.40%	56.42%	6.33%

All 55 Medical Instruments & Supplies stocks →